This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ariad Pharmaceutical's Iclusig May Relieve Shareholders' Pain: StockTwits

NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA - Get Report) released positive data Sunday for a drug intended to treat types of gastrointestinal tumors. The company said that initial data in its Phase 2 trial of Iclusig showed it has "anti-tumor activity" in patients with advanced gastrointestinal tumors that have proven resistant to other treatments.

Ariad rose nearly 10% in premarket trading to $7.09. By 10:30 a.m. the stock settled back to the $6.80 range, still up nearly 6%.

The overwhelming majority of traders on StockTwits.com called for the stock to go higher. Sentiment on the stock is 96% bullish, according to StockTwits analytics.

@SyntecVentures @FoxW Ill keep buying. These people know I'm not a seller of this stock till 20. It will be there by end of year ? Jared Mastroianni (@Stockbroker) Jun. 2 at 05:03 AM

The Phase 2 trial is ongoing. There are 35 patients involved and the FDA lifted a partial hold preventing Ariad from enrolling new patients.

$ARIA Solid science, solid leadership, minor setback. Time to recover & exceed!! This is Ariad goal, not sell cheap to please retail shares ? Sully (@SullyinFL) Jun. 2 at 07:27 AM

The FDA enacted the hold in October after some patients treated with Ariad's drug developed blood clots in their arteries. The prescriber's warning label for Iclusig says at least 27% of patients treated with the drug suffered a clot in arteries or veins. Patients with and without cardiovascular risk factors, including patients less than 50 years old, had clots. Heart failure, including fatalities, occurred in 8% of Iclusig-treated patients. The stock had dropped 59% on the October news.

$ARIA Morning all. Glad to see some love finally. Rough few months but patience pays. Cheers to a good day! ? Ben Parker (@Bparker5512) Jun. 2 at 07:51 AM

While side effects including a clot-induced stroke or heart attack are frightening, Iclusig is intended for people whose cancer type leaves them few other options. Patients can only enroll in the study if they have gastrointestinal stromal tumors that have spread to other organs and/or cannot be removed via surgery. In addition, they must also have cancer mutations that have made other treatments ineffective, such as tyrosine-kinase inhibitor treatments, which target cancers by interrupting signals to create more proteins that cause the tumor to spread.

Every year, 5,000 more people are diagnosed with gastrointestinal stromal tumors, according to the U.S. National Library of Medicine. The five-year survival rate for people who have such tumors and have had them spread to nearby organs is nearly 75%, according to Cancer.org.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARIA $8.97 0.00%
AAPL $129.96 0.00%
FB $80.44 0.00%
GOOG $539.18 0.00%
TSLA $248.35 0.00%

Markets

DOW 18,011.94 -28.43 -0.16%
S&P 500 2,109.60 -2.13 -0.10%
NASDAQ 5,076.5240 -6.4050 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs